AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profi
Go back to AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profi| (NASDAQ: ABCL) | Delayed: 12.70 +0.05 (0.40%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $12.65 | 52 Week High | $ | |||
| Open | $12.74 | 52 Week Low | $ | |||
| Day High | $12.93 | P/E | N/A | |||
| Day Low | $12.29 | EPS | $ | |||
| Volume | 3,382,858 | |||||
